migalastat (Rx)

Brand and Other Names:Galafold
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

capsule

  • 123mg

Fabry Disease

Treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data

123 mg PO once every other day at same time of day

Also see administration

Dosage Modifications

Renal impairment

  • Mild to moderate (eGFR ≥30 mL/min/1.73 m²): No dosage adjustment required
  • Severe (eGFR<30 mL/min/1.73 m²) or end-stage renal disease: Not recommended

Dosage Considerations

Consultation with a clinical genetics professional is strongly recommended in cases in which amenable GLA variant is of uncertain clinical significance (VUS, variant of uncertain significance) or may be benign (not causing Fabry disease)

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and migalastat

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            Headache (35%)

            Nasopharyngitis (18%)

            Urinary tract infection (15%)

            Nausea (12%)

            Pyrexia (12%)

            1-10%

            Abdominal pain (9%)

            Back pain (9%)

            Cough (9%)

            Diarrhea (9%)

            Epistaxis (9%)

            Previous
            Next:

            Warnings

            Contraindications

            None reported by the manufacturer

            Cautions

            This porduct was approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

            Previous
            Next:

            Pregnancy

            Pregnancy

            Available data are not sufficient to assess drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes; in animal reproduction studies, no adverse developmental effects were observed

            Infertility

            • Effects on fertility in humans not studied; transient and fully reversible infertility in male rats associated with treatment at systemic exposure (AUC) equivalent to human exposure at recommended dose; complete reversibility was seen at 4 weeks after termination of treatment; drug did not affect fertility in female rats

            Lactation

            There are no human data available on the presence of the drug in human milk, the effects on breastfed infant, or on milk production; the drug is present in the milk of lactating rats; when a drug is present in animal milk, it is likely that the drug will be present in human milk; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on the breastfed child from drug or from underlying maternal condition

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Binds to and stabilizes endogenous alpha-galactosidase A (alpha-Gal A) that is made in the patient’s own cells, with the intention of enabling its trafficking from the endoplasmic reticulum to lysosomes (designed to act as a “pharmacological chaperone”); once delivered to lysosomes, the alpha-Gal A enzyme can degrade the accumulated glycolipid (globotriaosylceramide [GL-3]) and globotriaosylsphingosine (lyso-Gb3)

            Certain GLA variants (mutations) causing Fabry disease result in production of abnormally folded and less stable forms of alpha-Gal A protein, which, however, retain enzymatic activity; those GLA variants, referred to as amenable variants, produce alpha-Gal A proteins that may be stabilized by migalastat, thereby restoring their trafficking to lysosomes and their intralysosomal activity

            Absorption

            Absolute bioavailability: ~ 75%

            Peak plasma time: 3 hr

            Plasma exposure (AUC and Cmax): Showed dose-proportional increases at oral doses from 75-1250 mg (doses from 0.5- to 8.3-fold of approved recommended dosage); drug does not accumulate following administration of drug every other day

            Effects of food

            • Administration 1 hr before a high-fat (850 calories; 56% from fat) or light meal (507 calories; 30% from fat), or 1 hr after a light meal, reduced the mean migalastat AUC by 37-42% and peak plasma concentration by 15-39% compared to fasting state

            Distribution

            Apparent volume of distribution (Vz/F): 89 L (range: 77-133 L) at steady state in Fabry patients

            Metabolism

            Based upon in vivo data, drug is a substrate for uridine diphosphate glucuronosyltransferase (UDPGT), a minor elimination pathway

            Elimination

            Urine (77%) and feces (20%)

            Half-life: 4 hr

            Clearance: 12.5 L/hr

            Previous
            Next:

            Administration

            Oral Administration

            Take on empty stomach; do not consume food at least 2 hr before and 2 hr after taking drug to give a minimum 4-hr fast; clear liquids can be consumed during this 4-hour period

            Not to be taken on 2 consecutive days

            Swallow capsules whole; do not cut, crush, or chew

            Missed dose

            • If dose missed entirely for the day, take missed dose only if within 12 hours of normal time dose should have been taken; if more than 12 hours passed, resume taking drug at next planned dosing day and time, according to every-other-day dosing schedule

            Storage

            Store at USP controlled room temperature of 20-25°C (68-77°F), with excursions permitted between 15° and 30°C (59° and 86°F)

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.